ATMP | Pharmaceuticals | Regulatory Rapporteur

Skip to main content
Skip to navigation

Advanced Therapy Medicinal Products

Recent advances and the near-term outlook for Advanced Therapy Medicinal Products in cancer treatment
2025-05-02T13:41:00+01:00
Case studies: The impact of the In Vitro Diagnostic Regulation on ATMP clinical trials and drug development plans
2025-05-02T13:41:00+01:00
May 2025 – Contents
2025-05-01T14:56:00+01:00
Gene Therapy Medicinal Products: An examination of regulatory CMC requirements
2025-05-01T09:43:00+01:00
EMA accepts new guidelines on investigational ATMPs
2025-02-17T12:54:00+00:00
Considerations in the development of allogenic and autologous cell therapies
2025-01-10T08:51:00+00:00

Small interfering RNA: regulatory challenges and therapeutic potential
2024-10-11T10:25:00+01:00
Near-term challenges of advanced therapy medicinal products: a maturing product class
2024-05-17T08:24:00+01:00
RegRapPod − May 2024
2024-05-08T16:30:00+01:00
Cell gene therapy: clinical trial application procedure of CAR-T therapy in the EU
2024-05-08T10:30:00+01:00
The first approval of a CRISPR-Cas9 gene editing medicinal product in the European Union: Casgevy
2024-05-08T10:30:00+01:00
Near-term challenges of advanced therapy medicinal products: a maturing product class
2024-05-08T10:00:00+01:00

More ATMP content